Cargando…
Ubenimex suppresses glycolysis mediated by CD13/Hedgehog signaling to enhance the effect of cisplatin in liver cancer
BACKGROUND: Liver cancer ranks third in fatalities among all cancer-related deaths. As a traditional chemotherapy drug, the application of cis-Diamminedichloroplatinum (II) (cisplatin, CDDP) for the treatment of liver cancer is greatly limited by its side effects and high drug resistance. Therefore,...
Autores principales: | Shi, Yunyan, Guo, Qie, Jing, Fanjing, Shang, Xiuling, Zhou, Changkai, Jing, Fanbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643970/ https://www.ncbi.nlm.nih.gov/pubmed/37969369 http://dx.doi.org/10.21037/tcr-23-435 |
Ejemplares similares
-
Ubenimex Suppresses the Ability of Migration and Invasion in Gastric Cancer Cells by Alleviating the Activity of the CD13/NAB1/MAPK Pathway
por: Liu, Xuehui, et al.
Publicado: (2021) -
CD13 downregulation mediated by ubenimex inhibits autophagy to overcome 5-FU resistance by disturbing the EMP3/FAK/NF-κB pathway in gastric cancer cells
por: Xiu, Ting, et al.
Publicado: (2022) -
Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells
por: Guo, Qie, et al.
Publicado: (2017) -
Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis
por: Guo, Qie, et al.
Publicado: (2019) -
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma
por: YAMASHITA, MASAFUMI, et al.
Publicado: (2016)